http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 11 Jun 2026 08:03:11 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) signed an exclusive patent licensing agreement with Florida State University for non-prescription use of Australian chestnut extract as a botanical supplement, the company announced.</p> <p>The license allows the pharmaceutical company to begin large-scale extraction of castanospermine from the seeds of Castanospermum australe, commonly known as the Australian Chestnut. Castanospermine serves as the principal component of Australian Chestnut Extract.</p> <p>The U.S. Food and Drug Administration issued a Non-Notification Letter to 60 Degrees Pharmaceuticals regarding the company's New Dietary Ingredient Notification filing for Australian Chestnut Extract. The company will meet with the FDA on July 1, 2026, to http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html Thu, 11 Jun 2026 08:03:11 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) signed an exclusive patent licensing agreement with Florida State University for non-prescription use of Australian chestnut extract as a botanical supplement, the company announced.</p> <p>The license allows the pharmaceutical company to begin large-scale extraction of castanospermine from the seeds of Castanospermum australe, commonly known as the Australian Chestnut. Castanospermine serves as the principal component of Australian Chestnut Extract.</p> <p>The U.S. Food and Drug Administration issued a Non-Notification Letter to 60 Degrees Pharmaceuticals regarding the company's New Dietary Ingredient Notification filing for Australian Chestnut Extract. The company will meet with the FDA on July 1, 2026, to http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html Thu, 11 Jun 2026 08:03:11 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) signed an exclusive patent licensing agreement with Florida State University for non-prescription use of Australian chestnut extract as a botanical supplement, the company announced.</p> <p>The license allows the pharmaceutical company to begin large-scale extraction of castanospermine from the seeds of Castanospermum australe, commonly known as the Australian Chestnut. Castanospermine serves as the principal component of Australian Chestnut Extract.</p> <p>The U.S. Food and Drug Administration issued a Non-Notification Letter to 60 Degrees Pharmaceuticals regarding the company's New Dietary Ingredient Notification filing for Australian Chestnut Extract. The company will meet with the FDA on July 1, 2026, to http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html Thu, 11 Jun 2026 08:03:11 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) signed an exclusive patent licensing agreement with Florida State University for non-prescription use of Australian chestnut extract as a botanical supplement, the company announced.</p> <p>The license allows the pharmaceutical company to begin large-scale extraction of castanospermine from the seeds of Castanospermum australe, commonly known as the Australian Chestnut. Castanospermine serves as the principal component of Australian Chestnut Extract.</p> <p>The U.S. Food and Drug Administration issued a Non-Notification Letter to 60 Degrees Pharmaceuticals regarding the company's New Dietary Ingredient Notification filing for Australian Chestnut Extract. The company will meet with the FDA on July 1, 2026, to http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html Thu, 11 Jun 2026 08:03:11 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) signed an exclusive patent licensing agreement with Florida State University for non-prescription use of Australian chestnut extract as a botanical supplement, the company announced.</p> <p>The license allows the pharmaceutical company to begin large-scale extraction of castanospermine from the seeds of Castanospermum australe, commonly known as the Australian Chestnut. Castanospermine serves as the principal component of Australian Chestnut Extract.</p> <p>The U.S. Food and Drug Administration issued a Non-Notification Letter to 60 Degrees Pharmaceuticals regarding the company's New Dietary Ingredient Notification filing for Australian Chestnut Extract. The company will meet with the FDA on July 1, 2026, to http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html Thu, 11 Jun 2026 08:03:11 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) signed an exclusive patent licensing agreement with Florida State University for non-prescription use of Australian chestnut extract as a botanical supplement, the company announced.</p> <p>The license allows the pharmaceutical company to begin large-scale extraction of castanospermine from the seeds of Castanospermum australe, commonly known as the Australian Chestnut. Castanospermine serves as the principal component of Australian Chestnut Extract.</p> <p>The U.S. Food and Drug Administration issued a Non-Notification Letter to 60 Degrees Pharmaceuticals regarding the company's New Dietary Ingredient Notification filing for Australian Chestnut Extract. The company will meet with the FDA on July 1, 2026, to http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html Thu, 11 Jun 2026 08:03:11 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) signed an exclusive patent licensing agreement with Florida State University for non-prescription use of Australian chestnut extract as a botanical supplement, the company announced.</p> <p>The license allows the pharmaceutical company to begin large-scale extraction of castanospermine from the seeds of Castanospermum australe, commonly known as the Australian Chestnut. Castanospermine serves as the principal component of Australian Chestnut Extract.</p> <p>The U.S. Food and Drug Administration issued a Non-Notification Letter to 60 Degrees Pharmaceuticals regarding the company's New Dietary Ingredient Notification filing for Australian Chestnut Extract. The company will meet with the FDA on July 1, 2026, to http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html Thu, 11 Jun 2026 08:03:11 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++60+DEGREES+PHARMACEUTICA++For%3A+Jun+08/26618347.html si-local-file:///var/storage/secattach/20260608/26618347.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++60+DEGREES+PHARMACEUTICA++For%3A+Jun+08/26618347.html Mon, 08 Jun 2026 17:14:00 -0400 O.58280676 SXTP http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++60+DEGREES+PHARMACEUTICA++For%3A+Jun+08/26618347.html si-local-file:///var/storage/secattach/20260608/26618347.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++60+DEGREES+PHARMACEUTICA++For%3A+Jun+08/26618347.html Mon, 08 Jun 2026 17:14:00 -0400 O.58280676 SXTP http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++60+DEGREES+PHARMACEUTICA++For%3A+Jun+03/26599991.html si-local-file:///var/storage/secattach/20260603/26599991.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++60+DEGREES+PHARMACEUTICA++For%3A+Jun+03/26599991.html Wed, 03 Jun 2026 16:57:00 -0400 O.58280676 SXTP http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++60+DEGREES+PHARMACEUTICA++For%3A+Jun+03/26599991.html si-local-file:///var/storage/secattach/20260603/26599991.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++60+DEGREES+PHARMACEUTICA++For%3A+Jun+03/26599991.html Wed, 03 Jun 2026 16:57:00 -0400 O.58280676 SXTP